NX Pharmagen
NX PharmaGen develops and monetizes mature clinical-stage technologies, focusing on disruptive diagnostic solutions.
Founded
2010NX PharmaGen develops and monetizes mature clinical-stage technologies, focusing on disruptive diagnostic solutions.
NX PharmaGen Inc. was founded to invest in and develop mature clinical-stage breakthrough technologies with a core mission to enrich patient lives through next-generation molecular diagnostics and imaging products. Their flagship product, the NeXosomeTM Platform, is a disruptive diagnostic technology aimed at improving patient outcomes, aiding physician decision-making, and enhancing payer economics. The company focuses on personalized medicine, leveraging advanced diagnostics to tailor treatments to individual patient needs.
Notable affiliated people and investors include leading experts in biotechnology and healthcare investment firms, although specific names are not disclosed. Key achievements of NX PharmaGen include the successful development and initial deployment of the NeXosomeTM Platform, which has shown promise in clinical settings. The overall impact of NX PharmaGen's innovations lies in their potential to revolutionize diagnostic processes, making personalized medicine more accessible and effective for patients worldwide.
Companies similar to NX Pharmagen include NX Prenatal, Phigenix, Nexosome Oncology and NexEos Diagnostics.
NX Pharmagen was founded in 2010.
NX Pharmagen's headquarters is located in Louisville, KY, US.
NX Pharmagen's most recent funding round was for $590k (USD) in October 2022.
As of Oct 21, 2022, NX Pharmagen has disclosed funding of $7.2M (USD). Undisclosed round amounts are excluded.
NX Pharmagen has 6 employees as of Feb 5, 2024.
NexEos Diagnostics
nexeosbio.com
